Number of Panel Genes21

The dominant & recessive Ehlers-Danlos syndrome NGS panel is designed to detect mutations in genes that cause clinical features related to Ehlers-Danlos syndrome (EDS). EDS is a connective tissue disorder characterized by joint hypermobility, skin hyperextensibility and tissue fragility. There are numerous subtypes of EDS each with distinct genetic and clinical findings.

The dominant & recessive Ehlers-Danlos syndrome NGS panel is designed to detect mutations in genes that cause clinical features related to Ehlers-Danlos syndrome (EDS). EDS is a connective tissue disorder characterized by joint hypermobility, skin hyperextensibility and tissue fragility. There are numerous subtypes of EDS each with distinct genetic and clinical findings. CTGT offers several panel options for Ehlers-Danlos syndrome testing including a classic type panel, a core panel, a dominant panel, a recessive panel and a combined dominant and recessive panel. In addition to genes associated with the dominant and recessive forms of EDS, the panels also contain genes for disorders included in the differential diagnosis of EDS.

The dominant & recessive Ehlers-Danlos syndrome NGS panel consists of twenty-one genes: ADAMTS2, AEBP1, ATP7A, B3GALT6,  B4GALT7, C1R, C1S, CHST14, COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, COL12A1, DSE, FKBP14, FLNA, PLOD1, PRDM5, SLC39A13 and ZNF469.

Copy number variation (CNV) analysis of the dominant & recessive Ehlers-Danlos syndrome genes is also offered as a panel. Additionally, CTGT offers a comprehensive test (both NGS and CNV panels) for these genes. Panel genes are also offered as individual sequencing and deletion/duplication tests unless otherwise indicated

Dominant EDS Panel 

Gene Disorder MIM Inheritance
C1R Ehlers-Danlos syndrome, periodontal type 1 (EDSPD1) 130080 AD
C1S Ehlers-Danlos syndrome, periodontal type 2 (EDSPD2) 617174 AD
COL5A1 Ehlers-Danlos syndrome, classic type, 1 (EDSCL1) 130000 AD
COL5A2 Ehlers-Danlos syndrome, classic type, 2 (EDSCL2) 130010 AD
COL3A1 Ehlers-Danlos syndrome, vascular type (EDSVASC) 130050 AD
COL1A1 Ehlers-Danlos syndrome, arthrochalasia type, 1 (EDSARTH1) 130060 AD
COL1A2 Ehlers-Danlos syndrome, arthrochalasia type, 2 (EDSARTH2) 617821 AD
COL12A1 Bethlem myopathy 2 (BTHLN2) 616471 AD
FLNA Periventricular nodular heterotopia 1 (PVNH1) 300049 XLD

 

Recessive EDS Panel

Gene Disorder MIM Inheritance
ADAMTS2 Ehlers-Danlos syndrome, dermatosparaxis type (EDSDERMS) 225410 AR
AEBP1 Ehlers-Danlos syndrome, classic-like, 2 (EDSCLL2) 618000 AR
ATP7A Occipital horn syndrome (OHS) 304150 XLR
B3GALT6 Ehlers-Danlos syndrome, spondylodysplastic type, 2 (EDSSPD2) 615349 AR
B4GALT7 Ehlers-Danlos syndrome, spondylodysplastic type, 1 (EDSSPD1) 130070 AR
CHST14 Ehlers-Danlos syndrome, musculocontractural type 1 (EDSMC1) 601776 AR
COL1A2 Ehlers-Danlos syndrome, cardiac valvular type (EDSCV) 225320 AR
DSE Ehlers-Danlos syndrome, musculocontractural type, 2 (EDSMC2) 615539 AR
FKBP14 Ehlers-Danlos syndrome, kyphoscoliotic type, 2 (EDSKSCL2) 614557 AR
PLOD1 Ehlers-Danlos syndrome, kyphoscoliotic type, 1 (EDSKSCL1) 225400 AR
PRDM5 Brittle cornea syndrome 2 (BCS2) 614170 AR
SLC39A13 Ehlers-Danlos syndrome, spondylodysplastic type, 3 (EDSSPD3) 612350 AR
ZNF469 Brittle cornea syndrome 1 (BCS1) 229200 AR

Gene(s)

ADAMTS2 AEBP1 ATP7A B3GALT6 B4GALT7 C1R C1S CHST14 COL12A1 COL1A1 COL1A2 COL3A1 COL5A1 COL5A2 DSE FKBP14 FLNA PLOD1 PRDM5 SLC39A13 ZNF469

Disease Group

Connective tissue Cardiovascular disorders Skin, Tooth, Hair and Nail disorders

MIM

130000 130010 130050 130060 300537 225410 304150 601776 614505 225400 612350

Methodology

Billing

CPT Code(s)
81408 x 1, 81479 x 1

Ordering

Test Code
5069

Additional Test Codes
5067 —Next Generation Sequencing Only, 5068 — Deletion / Duplication Only

Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.

Prenatal Specimens
Cultured cells: 2 confluent T-25 flasks derived from amnio or CVS samples
Genomic DNA: minimum of 3 µg (at a concentration of at least 30 ng/µl)

Non-Prenatal Specimens
Whole blood: purple-top (EDTA) tube, minimum of 3 ml
Genomic DNA: a minimum of 3 µg (at a concentration of at least 30 ng/µl)
Fibroblasts: 2 confluent T-25 flasks
Saliva: only samples collected in Oragene DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children are accepted

Shipping
Ship all specimen types at room temperature by overnight courier. Do not freeze.

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

News

October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More